Hematology and Hemostasis

  • Jürgen Finke
  • Hartmut Bertz
  • Anna-Katharina Kaskel
  • Jürgen Heinz
  • A.K. Thomas
  • Dietmar P. Berger
  • Rupert Engelhardt
  • Oliver Schmah


Folic Acid Hemolytic Anemia Aplastic Anemia Disseminate Intravascular Coagulation Fresh Freeze Plasma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bacigalupo A, Bruno B, Saracco P et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT Working Party. Blood 2000;95:1931–34PubMedGoogle Scholar
  2. 2.
    Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000;110:41–53PubMedCrossRefGoogle Scholar
  3. 3.
    Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647–56PubMedCrossRefGoogle Scholar
  4. 4.
    Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007;136:549–64PubMedCrossRefGoogle Scholar
  5. 5.
    Geroges GE, Storb R. Stem cell transplantation for aplastic anemia. Int J Hematol 2002;75:141–6CrossRefGoogle Scholar
  6. 6.
    Kojima S, Hibi S, Kosaka Y et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporin, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049–54PubMedGoogle Scholar
  7. 7.
    Marsh JCW, Ball SE, Darbyshire P et al. British Committee for Standards in Hematology (BCSH). Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol 2003;123:782–90PubMedCrossRefGoogle Scholar
  8. 8.
    Yamaguchi H, Calado RT, Ly H et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413–24PubMedCrossRefGoogle Scholar
  9. 9.
    Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002;75:129–40PubMedCrossRefGoogle Scholar
  10. 1. AA and MDS FoundationGoogle Scholar
  11. 2. Fanconi Anemia Research FundGoogle Scholar
  12. 1.
    Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology (ASH Educ Program) 2004:63–79Google Scholar
  13. 2.
    Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 2007;49:609–14PubMedCrossRefGoogle Scholar
  14. 3.
    Lakshman R, Finn A. Neutrophil disorders and their management. J Clin Pathol 2001;54:7–19PubMedCrossRefGoogle Scholar
  15. 4.
    Manny N, Zelig O. Laboratory diagnosis of autoimmune cytopenias. Curr Opin Hematol 2000;7:414–9PubMedCrossRefGoogle Scholar
  16. 5.
    Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious and idiosyncratic neutropenias. Semin Hematol 2002;39:113–20PubMedCrossRefGoogle Scholar
  17. 6.
    Welte G, Zeidler C, Dole DC. Severe congenital neutropenia. Semin Hematol 2006;43:189–95PubMedCrossRefGoogle Scholar
  18. 1. NORD, Rare DisordersGoogle Scholar
  19. 2. Medline Plus articleGoogle Scholar
  20. 3. MASCC, Supportive CareGoogle Scholar
  21. 4. Neutropenia Support AssocGoogle Scholar
  22. 5. E-medicineGoogle Scholar
  23. 6.
    Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580–7PubMedCrossRefGoogle Scholar
  24. 7.
    Bolton-Maggs PHB, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–33PubMedCrossRefGoogle Scholar
  25. 8.
    Cines DB, Bussel JB, McMillan RB et al. Congenital and acquired thrombocytopenia. Hematology (ASH Educ Program) 2004:390–406Google Scholar
  26. 9.
    Deutsch VR, Tomer A. Megakaryocyte development and platelet production: Br J Haematol 2006;
134:453–66PubMedCrossRefGoogle Scholar
  27. 10.
    Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390–8PubMedCrossRefGoogle Scholar
  28. 11.
    Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004;16:15–22PubMedCrossRefGoogle Scholar
  29. 12.
    George JN. Platelets. Lancet 2000;355:1531–9PubMedCrossRefGoogle Scholar
  30. 13.
    Jelic S, Radulovic S. Chemotherapy-associated thrombocytopenia. Ann J Cancer 2006;5:371–82CrossRefGoogle Scholar
  31. 1. Platelet Disorder Support AssocGoogle Scholar
  32. 2. ISTH, Intl Soc Thromb HemostasisGoogle Scholar
  33. 3.
article/000586.htm MedlinePlusGoogle Scholar
  34. 4. E-medicineGoogle Scholar
  35. 5. NCI, Marrow Failure DisordersGoogle Scholar
  36. 6.
    Andemariam B, Bussel J. New therapies for ITP. Curr Opin Hematol 2007;14:427–31PubMedCrossRefGoogle Scholar
  37. 7.
    British Committee for Standards in Hematology (BCSH). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol 2003;120:574–96CrossRefGoogle Scholar
  38. 8.
    Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672–81PubMedCrossRefGoogle Scholar
  39. 9.
    Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425–42PubMedCrossRefGoogle Scholar
  40. 10.
    George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med 1998;30:38–44PubMedCrossRefGoogle Scholar
  41. 11.
    McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004;104:956–60PubMedCrossRefGoogle Scholar
  42. 12.
    Portielle JEA, Westendorp RGJ, Kluin-Nelemans et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54CrossRefGoogle Scholar
  43. 13.
    Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436–42PubMedCrossRefGoogle Scholar
  44. 1. PDSAGoogle Scholar
  45. 2. E-medicineGoogle Scholar
  46. 3. E-medicineGoogle Scholar
  47. 4. Scripps ClinicGoogle Scholar
  48. 5. ITP Support AssocGoogle Scholar
  49. 1.
    Alving BM. How I treat heparin-induced thrombopenia and thrombosis. Blood 2003;101:31–7PubMedCrossRefGoogle Scholar
  50. 2.
    Arepally GM, Ortel TL. Hepanin-induced thrombocytopenia. N Engl J Med 2006;355:809–17PubMedCrossRefGoogle Scholar
  51. 3.
    Keeling D, Davidson S, Watson H. British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259–69PubMedCrossRefGoogle Scholar
  52. 4.
    Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182–7PubMedGoogle Scholar
  53. 5.
    Rice L, Attisha WK, Drexler A et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210–5PubMedGoogle Scholar
  54. 1. Intl Soc Thrombosis HemostasisGoogle Scholar
  55. 2. TIGC, GuidelinesGoogle Scholar
  56. 1.
    Allford SL, Hunt BJ, Rose P et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic purpura. Br J Haematol 2003;120:556–73PubMedCrossRefGoogle Scholar
  57. 2.
    George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–35PubMedCrossRefGoogle Scholar
  58. 3.
    Ho VT, Cutler C, Carter S et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571–5PubMedCrossRefGoogle Scholar
  59. 4.
    Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11–17PubMedCrossRefGoogle Scholar
  60. 5.
    Plaimauer B, Zimmermann K, Volkel D et al. Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100:3626–32PubMedCrossRefGoogle Scholar
  61. 6.
    Richards A, Goodship JA, Goodship THJ. The genetics and pathogenesis of HUS and TTP. Curr Opin Nephrol Hypertens 2002;11:431–5PubMedCrossRefGoogle Scholar
  62. 7.
    Sadler JE, Moake JL, Miyata T et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology (ASH Educ Program) 2004:407–23Google Scholar
  63. 8.
    Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uremic syndrome. Lancet 2005;365:1073–86PubMedCrossRefGoogle Scholar
  64. 1. TTP-HUS RegistryGoogle Scholar
  65. 2. TTP, E-medicineGoogle Scholar
  66. 3. HUS, E-medicineGoogle Scholar
  67. 4. Puget Sound Blood CenterGoogle Scholar
  68. 5. TTP FoundationGoogle Scholar
  69. 6. MedlinePlusGoogle Scholar
  70. 7. MedlinePlusGoogle Scholar
  71. 1.
    Birgegard G, Aapro MS, Bokemeyer C et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(suppl 1):3–11PubMedCrossRefGoogle Scholar
  72. 2.
    Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201–16PubMedCrossRefGoogle Scholar
  73. 3.
    British Committee for Standards in Hematology (BCSH). Guidelines for the clinical use of red cell transfusion. Br J Haematol 2001;113:24–31CrossRefGoogle Scholar
  74. 4.
    Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(suppl 8):49–53PubMedCrossRefGoogle Scholar
  75. 5.
    Provan D, Weatherall D. Red cells I: inherited anaemias. Lancet 2000;355:1169–75PubMedCrossRefGoogle Scholar
  76. 6.
    Provan D, Weatherall D. Red cells II: acquired anemias and polycythaemia. Lancet 2000;355:1260–8PubMedCrossRefGoogle Scholar
  77. 7.
    Rizzo JD, Somerfield MP, Hagerty KL et al. ASH/ASCO 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 2007;111:x–yGoogle Scholar
  78. 1. Anemia InstituteGoogle Scholar
  79. 2. Guideline ClearinghouseGoogle Scholar
  80. 3. MedlinePlusGoogle Scholar
  81. 4. Anemia Action CouncilGoogle Scholar
  82. 1.
    Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J 2004;5:373–80PubMedCrossRefGoogle Scholar
  83. 2.
    Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823–33PubMedCrossRefGoogle Scholar
  84. 3.
    Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(2 suppl 8):49–53PubMedCrossRefGoogle Scholar
  85. 4.
    Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999;70:7–12PubMedGoogle Scholar
  86. 5.
    Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14–23PubMedCrossRefGoogle Scholar
  87. 6.
    Umbreit J. Iron deficiency. Am J Hematol 2005;78:435–43CrossRefGoogle Scholar
  88. 7.
    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–23PubMedCrossRefGoogle Scholar
  89. 8.
    Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370:511–20PubMedCrossRefGoogle Scholar
  90. 1. Medline PlusGoogle Scholar
  91. 2. Medline PlusGoogle Scholar
  92. 3. Univ MarylandGoogle Scholar
  93. 4. E-medicineGoogle Scholar
  94. 1.
    Dharmarajan TS, Norkus EP. Approaches to vitamin B12 deficiency. Early treatment may prevent devastating complications. Postgrad Med 2001;110:99–105PubMedCrossRefGoogle Scholar
  95. 2.
    Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57–67PubMedCrossRefGoogle Scholar
  96. 3.
    Provan D, Weatherall D. Red cells II: acquired anaemias and polycythaemia. Lancet 2000;355:1260–8PubMedCrossRefGoogle Scholar
  97. 4.
    Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997;337:1441–8PubMedCrossRefGoogle Scholar
  98. 5.
    Wickramashinghe SN. The wide spectrum and unresolved issues of megaloblastic anemia. Semin Hematol 1999;36:3–18Google Scholar
  99. 6.
    Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol 1999;36:35–46PubMedGoogle Scholar
  100. 1. Medline PlusGoogle Scholar
  101. 2. Introduction to VitaminsGoogle Scholar
  102. 3. Univ MarylandGoogle Scholar
  103. 4. E-medicineGoogle Scholar
  104. 5. ASH Image BankGoogle Scholar
  105. 6.
    Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007;138:291–304PubMedCrossRefGoogle Scholar
  106. 7.
    British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004;126:455–74CrossRefGoogle Scholar
  107. 8.
    Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol 2004;41:142–64PubMedCrossRefGoogle Scholar
  108. 9.
    Gertz A. Management of cold haemolytic syndrome. Br J Haematol 2007;138:422–9PubMedCrossRefGoogle Scholar
  109. 10.
    Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in PNH N Engl J Med 2006;355:1233–43PubMedCrossRefGoogle Scholar
  110. 11.
    King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol 2005;42:131–6PubMedCrossRefGoogle Scholar
  111. 12.
    Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol 2000;13:21–38PubMedGoogle Scholar
  112. 13.
    Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343–60PubMedCrossRefGoogle Scholar
  113. 1. Medline PlusGoogle Scholar
  114. 2. Medline PlusGoogle Scholar
  115. 3. Univ MarylandGoogle Scholar
  116. 4. Family PracticeGoogle Scholar
  117. 5. E-medicineGoogle Scholar
  118. 1.
    Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000;53(1 suppl):S2–8PubMedCrossRefGoogle Scholar
  119. 2.
    Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 2000;20:320–9PubMedCrossRefGoogle Scholar
  120. 3.
    MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375–81PubMedCrossRefGoogle Scholar
  121. 4.
    Ritz E, Schwenger V. The optimal target hemoglobin. Semin Nephrol 2000;20:382–6PubMedGoogle Scholar
  122. 5.
    Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000;15(suppl 3):23–8PubMedCrossRefGoogle Scholar
  123. 1.
doqianemia.html National Kidney Foundation GuidelinesGoogle Scholar
  124. 2. Anemia InstituteGoogle Scholar
  125. 3. American Society of NephrologyGoogle Scholar
  126. 4.
    Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133:19–34PubMedCrossRefGoogle Scholar
  127. 5.
    Dahlback B. Blood coagulation. Lancet 2000;355:1627–32PubMedCrossRefGoogle Scholar
  128. 6.
    Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001;31(suppl 1):1–4PubMedGoogle Scholar
  129. 7.
    Manucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–52CrossRefGoogle Scholar
  130. 8.
    Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005;2:356–63PubMedGoogle Scholar
  131. 1. ISTHGoogle Scholar
  132. 2. Washington UnivGoogle Scholar
  133. 3. Indiana State UnivGoogle Scholar
  134. 4. Medline PlusGoogle Scholar
  135. 1.
    Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257:209–23PubMedCrossRefGoogle Scholar
  136. 2.
    Delgado J, Jimenez-Yuste V, Hernandez-Navarro F et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21–35PubMedCrossRefGoogle Scholar
  137. 3.
    Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–63PubMedCrossRefGoogle Scholar
  138. 4.
    Li T, Chang CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541–4PubMedCrossRefGoogle Scholar
  139. 5.
    Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426–8PubMedCrossRefGoogle Scholar
  140. 6.
    Zeitler H, Ulrich-Merzenich G, Hess L et al. Treatment of acquired hemophilia by the Bonn-Malmö protocol. Blood 2005;105:2287–93PubMedCrossRefGoogle Scholar
  141. 1. Intl Soc Thrombosis HemostasisGoogle Scholar
  142. 2. Vitamin K DeficiencyGoogle Scholar
  143. 3. E-MedicineGoogle Scholar
  144. 4.
article/002407.htm Medline PlusGoogle Scholar
  145. 1.
    Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001;7:109–13PubMedCrossRefGoogle Scholar
  146. 2.
    Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet 2003;361:1801–9PubMedCrossRefGoogle Scholar
  147. 3.
    Evatt BL, Farrugia A, Shapiro AD et al. Haemophilia 2002: emerging risks of treatment. Haemophilia 2002;8:221–9PubMedCrossRefGoogle Scholar
  148. 4.
    Graw J, Brackmann HH, Oldenburg J et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005;6:488–501PubMedCrossRefGoogle Scholar
  149. 5.
    Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317–32PubMedCrossRefGoogle Scholar
  150. 6.
    Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol 2004;127:12–25PubMedCrossRefGoogle Scholar
  151. 7.
    Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9:27–31PubMedCrossRefGoogle Scholar
  152. 1. Haemophilia ForumGoogle Scholar
  153. 2. Natl Hemophilia FoundationGoogle Scholar
  154. 3. Haemophilia SocietyGoogle Scholar
  155. 4. World Fed HemophiliaGoogle Scholar
  156. 5. Medline PlusGoogle Scholar
  157. 6. International Society of Thrombosis and HemostasisGoogle Scholar
  158. 1.
    Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(suppl 1):1–4PubMedCrossRefGoogle Scholar
  159. 2.
    Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet 2003;361:1801–9PubMedCrossRefGoogle Scholar
  160. 3.
    Di Michele D. Inhibitor development in haemophilia B. Br J Haematol 2007;138:305–15CrossRefGoogle Scholar
  161. 4.
    Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317–32PubMedCrossRefGoogle Scholar
  162. 5.
    Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol 2004;127:12–25PubMedCrossRefGoogle Scholar
  163. 6.
    Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005;CD003429Google Scholar
  164. 7.
    Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9:27–31PubMedCrossRefGoogle Scholar
  165. 1. Hemophilia B DatabaseGoogle Scholar
  166. 2. Haemophilia ForumGoogle Scholar
  167. 3. Natl Hemophilia FoundationGoogle Scholar
  168. 4. Haemophilia SocietyGoogle Scholar
  169. 5. World Fed HemophiliaGoogle Scholar
  170. 6. Medline PlusGoogle Scholar
  171. 7. International Society of Thrombosis and HemostasisGoogle Scholar
  172. 1.
    Battle J, Noya MS, Giangrande P et al. Advances in the therapy of von Willebrand disease. Haemophilia 2002;8:301–7CrossRefGoogle Scholar
  173. 2.
    Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999;82:585–91PubMedCrossRefGoogle Scholar
  174. 3.
    Manucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004;351:683–94CrossRefGoogle Scholar
  175. 4.
    Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005;42:29–35PubMedCrossRefGoogle Scholar
  176. 5.
    Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000;84:147–9PubMedGoogle Scholar
  177. 6.
    Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–74PubMedGoogle Scholar
  178. 7.
    Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol 2005;42:15–28PubMedCrossRefGoogle Scholar
  179. 1. ISTH VWF DatabaseGoogle Scholar
  180. 2. VWD ResourceGoogle Scholar
  181. 3.
article/000544.htm VWD, Medline PlusGoogle Scholar
  182. 4. Hemophilia FoundationGoogle Scholar
  183. 5. World Fed HemophiliaGoogle Scholar
  184. 6. Canadian Hemophilia SocGoogle Scholar
  185. 7. E-MedicineGoogle Scholar
  186. 1.
    Bernard GR, Vincent JH, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709PubMedCrossRefGoogle Scholar
  187. 2.
    De Cicco M. The prothrombotic state in cancer: pathogenetic mechanisms. Crit Rev Hematol Oncol 2004;50:187–96CrossRefGoogle Scholar
  188. 3.
    Franchini M, Manzato F. Update on the treatment of disseminated intravascular coagulation. Hematology 2004;9:81–5PubMedCrossRefGoogle Scholar
  189. 4.
    Levi M. Disseminated intravascular coagulation: what’s new? Crit Care Clin 2005;21:449–67PubMedCrossRefGoogle Scholar
  190. 5.
    Toh CH, Dennis M. DIC 2002: a review of disseminated intravascular coagulation. Hematology 2003;8:65–71PubMedCrossRefGoogle Scholar
  191. 6.
    Warren BL, Reid A, Singer P et al. High dose antithrombin III in severe sepsis. JAMA 2001;286:1869–78PubMedCrossRefGoogle Scholar
  192. 7.
    Yanada M, Matsushita T, Suzuki M et al. DIC in acute leukemia: clinical and laboratory features at presentation. Eur J Haematol 2006;77:282–7PubMedCrossRefGoogle Scholar
  193. 1. Intl Soc Thromb HaemostGoogle Scholar
  194. 2. Medline PlusGoogle Scholar
  195. 3. E-medicineGoogle Scholar
  196. 1.
    Baglin IP, Cousins D, Keeling DM et al. Recommendations from the British Committee for Standard in Haematology and National Patient Safety Agency. Br J Haematol 2006;136:26–9PubMedCrossRefGoogle Scholar
  197. 2.
    British Committee for Standards in Haematology (BCSH). Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512–28CrossRefGoogle Scholar
  198. 3.
    Francis CW. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl Med 2007;356:1438–44CrossRefGoogle Scholar
  199. 4.
    Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–5PubMedCrossRefGoogle Scholar
  200. 5.
    Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163–74PubMedCrossRefGoogle Scholar
  201. 6.
    Lee AYY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123–9PubMedCrossRefGoogle Scholar
  202. 7.
    Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (ASH Educ Program) 2004;439–56Google Scholar
  203. 8.
    Lyman GH, Khorana AA, Falanga A et al. ASCO Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:x–yCrossRefGoogle Scholar
  204. 1. Medline PlusGoogle Scholar
  205. 2. E-MedicineGoogle Scholar
  206. 3. ISTHGoogle Scholar
  207. 4. Thrombosis Res InstGoogle Scholar
  208. 5. TIGCGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Jürgen Finke
    • 1
  • Hartmut Bertz
    • 2
  • Anna-Katharina Kaskel
    • 3
  • Jürgen Heinz
    • 3
  • A.K. Thomas
  • Dietmar P. Berger
    • 3
  • Rupert Engelhardt
    • 4
  • Oliver Schmah
    • 1
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  3. 3.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  4. 4.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany

Personalised recommendations